This study identifies TET2-mutant clonal hematopoiesis in thyroid cancer microenvironments and shows that TGFβ signaling from these macrophages mediates resistance to BRAF/MEK inhibition, with TGFβ inhibition restoring sensitivity.

bioRxiv · Oct 10, 2024 · PreprintCancer Biology

Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, Yasuhito Nannya, Robert Paul Hasserjian, Sean M. Devlin, Heinz Tuechler, Juan Santiago Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max Fine Levine, Juan E. Arango, Yangyu Zhou, Francesc Gessé Solé, Catherine A. Cargo, , Elli Papaemmanuil

The paper examines TP53 allelic states in MDS patients, finding that bi-allelic targeting is linked to worse outcomes, while mono-allelic targeting does not differ from wild-type patients.

Nature Medicine · Aug 3, 2020Peer-reviewedGenomics

Oncologic Therapy Shapes the Fitness Landscape of ClonalHematopoiesis

Kelly L. Bolton, Ryan N. Ptashkin, Teng Gao, Lior Zvi Braunstein, Sean M. Devlin, Daniel John Kelly, Minal A. Patel, Antonin Berthon, Aijazuddin Syed, Mariko Yabe, Catherine Callaghan Coombs, Nicole M. Caltabellotta, Mike Walsh, Kenneth Offit, Zsofia Kinga Stadler, , Elli Papaemmanuil

The paper shows oncologic therapy increases clonal hematopoiesis with DDR mutations, which predicts risk of therapy-related myeloid neoplasms.

bioRxiv · Nov 20, 2019 · PreprintGenetics